Overview

• altSonflex1-2-3 uses GSK’s Generalized Modules for Membrane Antigens technology to deliver O antigens via bacterial outer membranes for high-yield, cost-effective production.
• Phase 1 trials in Europe and Phase 2 trials in Africa, including nine-month-old infants, showed strong safety and immunogenicity with no adverse safety signals.
• Bharat Biotech will oversee Phase 3 clinical trials alongside regulatory filings and scale-up manufacturing for global distribution.
• This collaboration builds on a 2021 product transfer and license agreement between GSK and Bharat Biotech for the RTS,S malaria vaccine.
• Shigellosis currently has no licensed vaccine and causes severe gastrointestinal illness worldwide, making this candidate a key public health priority.